FR940617-1-00054 FR940617-1-00012 (38) Letter from W. E. Gilbertson, FDA, to M. K. Bruch, Dexide, Inc., coded LET79, Docket No. 75N&hyph;0183, Dockets Management Branch. (39) Memorandum of meeting between representatives of Dexide, Inc., Ferro Corp., and FDA, coded MM11, Docket No. 75N&hyph;0183, Dockets Management Branch. (40) Letter from W. E. Gilbertson, FDA, to M. K. Bruch, Dexide, Inc., coded LET89, Docket No. 75N&hyph;0183, Dockets Management Branch. (41) Comment No. C165, Docket No. 75N&hyph;0183, Dockets Management Branch. (42) Comment No. SUP51, Docket No. 75N&hyph;0183, Dockets Management Branch. (43) Letter from W. E. Gilbertson, FDA, to M. K. Bruch, Dexide, Inc., coded LET93, Docket No. 75N&hyph;0183, Dockets Management Branch. (44) Memorandum of meeting between representatives of Dexide, Inc., Ferro Corp., and FDA, coded MM15, Docket No. 75N&hyph;0183, Dockets Management Branch. (45) Comment No. C172, Docket No. 75N&hyph; 0183, Dockets Management Branch. (46) Letter from W. E. Gilbertson, FDA, to G. R. Kramzar, NIPA Laboratories, Inc., coded LET97, Docket No. 75N&hyph;0183, Dockets Management Branch. (47) Letter from W. E. Gilbertson, FDA to G. R. Kramzar, NIPA Laboratories, Inc., coded C174, Docket No. 75N&hyph;0183, Dockets Management Branch. (48) Comment No. C173, Docket No. 75N- 0183, Dockets Management Branch. (49) Comment No. LET65, vol. 4, 5, and 6, Docket No. 75N&hyph;0183, Dockets Management Branch. (50) McCracken, A., ``Effectiveness of Ultradex Scrub Sponge Determined in a Clinical Setting,'' unpublished study, coded LET65, vol. 6, Docket No. 75N&hyph;0183, Dockets Management Branch. (51) Letter from W. E. Gilbertson, FDA, to M. K. Bruch, Dexide, Inc., coded LET87, Docket No. 75N&hyph;0183, Dockets Management Branch.
